Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15232009 | 0.98 | MAOB (0.51) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| SCHEMBL20641173 | 0.86 | DYRK1A (0.63) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| SCHEMBL28407576 | 0.86 | MAOB (0.50) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| SCHEMBL12327197 | 0.84 | MAOB (0.51) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| SCHEMBL160745 | 0.84 | MAOB (0.51) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| SCHEMBL15038280 | 0.84 | MAOB (0.55) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL30259053 | 0.82 | MAOB (0.50) | MAOBNAMPTMEN1CYP1A2KMT2A | |
| SCHEMBL15377241 | 0.81 | MCHR1 (0.55) | MAOBNAMPTMEN1KMT2AMCHR1 | |
| SCHEMBL15246316 | 0.81 | NAMPT (0.73) | NAMPTHDAC1CYP2C9 | |
| SCHEMBL24087277 | 0.80 | MAOB (0.48) | MAOBNAMPTMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | claimed |
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | claimed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| JP-2011529057-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | claimed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | claimed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025122558-A1 | PYRAZINAMIDE-MIMICKING SMALL MOLECULES AS TREATMENT FOR TUBERCULOSIS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| WO-2004046144-A1 | 8-SUBSTITUTED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | WO | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003070732-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | MAOB 1942/4885NAMPT 643/4885MEN1 4117/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MAOB 165/4885NAMPT 4738/4885MEN1 4537/4885 |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | MAOB 326/4885NAMPT 353/4885MEN1 220/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | MAOB 105/4885NAMPT 1/4885MEN1 491/4885 |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | MAOB 1018/4885NAMPT 3096/4885MEN1 150/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | MAOB 1846/4885NAMPT 2310/4885MEN1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.